Tekamlo and Breastfeeding

Women who are breastfeeding should not take Tekamlo (aliskiren/amlodipine). Although it is not known if the drug passes through breast milk in humans, the possibility certainly exists and the effects it would have on a nursing infant are unknown. Together, you and your healthcare provider can weigh the benefits and risks in order to determine what is best for your situation.

Can I Use Tekamlo While Breastfeeding?

At this time, it is unknown if Tekamlo™ (aliskiren/amlodipine) passes through breast milk. The manufacturer recommends that breastfeeding women avoid Tekamlo. Thus, if you are breastfeeding or are thinking about it, you should discuss the issue with your healthcare provider first.

What Does the Research Say?

Tekamlo contains two different medications: aliskiren (Tekturna®) and amlodipine (Norvasc®). No studies have been done to see if either medication passes through breast milk in women. However, both have been shown to pass through breast milk in rats, which is a good indication that it probably does so in humans as well.
In addition, if Tekamlo does indeed pass through breast milk in humans, the effects it would have on a breastfeeding infant are unknown.

Discussing Breastfeeding and Tekamlo With Your Healthcare Provider

You should talk with your healthcare provider about Tekamlo and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.
7 Easy Tips for Starting Solids

Tekamlo Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.